Industry Outlook
Devic’s syndrome (Neuromyelitis optica) treatment accounted for a market value of US$ 156.8 Mn in 2018 and projected to grow at a CAGR of 12.0% during the forecast period from 2019 to 2027. Devic's disease or neuromyelitis optica is an autoimmune disease in which antibodies and immune system cells mainly damage the optic nerves and the spinal cord, but in a few cases affect the brain. The injury to optical nerves leads to inflammation and soreness leading to vision loss and pain; the injury to the spinal cord leads to paralysis in the arms or legs, loss of sensation, and problems with bladder & bowel function. The key factors responsible for growth of global Devic’s syndrome treatment market are rising awareness & prevalence related to orphan diseases, recent launch of first-target specific drug Soliris (Eculizumab) and strong drug pipeline expected to provide significant growth in the market.
Market Synopsis
Get a sample copy for more information
"Soliris (Eculizumab) will aid the significant growth of Devic’s Syndrome treatment market throughout the forecast period"
Soliris (Eculizumab) is a terminal complement inhibitor owned by Alexion. Soliris works by specifically preventing activation of particular proteins in the complement system (C5a and C5b), which play a role in the treatment of Devic’s syndrome. Patients suffering with Devic’s syndrome possess AQP4 antibody-positive, the body’s immune system can turn against itself to produce autoantibodies against AQP4. Activation of anti-AQP4 autoantibodies leads to damage of vital cells in the CNS assisting further demyelination and death of neurons, primarily in the optic nerve and spinal cord. There are three promising molecules in Devic’s syndrome treatment pipeline such as Satralizumab – Phase 3 (Hoffmann-La Roche/ Chugai Pharmaceutical), MEDI-551- Phase 2/3 (MedImmune LLC), and RC18 – Phase 3 (RemeGen, Ltd.). Chugai Pharmaceutical launched Phase 2 results related to Satralizumab on 15 October 2018; it is an investigational humanized anti-IL-6 receptor recycling monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
Get a sample copy for more information
"North America dominated the overall global market specifically due to recent drug approval, promising drugs in pipeline, and developed diagnostic landscape"
In 2018, North America dominated the market and anticipated to retain its position throughout the forecast period due to high awareness related to orphan diseases, rising requirement for target-specific molecules to treat Devic’s Syndrome, and easy adaptability & accessibility for newly launched drug. According to National Multiple Sclerosis Society, there are around 4,000 people suffering with Devic’s syndrome in the United States with majority of women population. Asia Pacific will grow during the forecast period from 2019 to 2027, due to increasing awareness related to Devic’s Syndrome assisting the rise in diagnosis & treatment rate in patients suffering with rare diseases.
Get a sample copy for more information
Historical & Forecast Period
The Devic’s Syndrome treatment market analyzed considering current market trends for base year 2018 and based on future trends CAGRs calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
This report comprises in-depth information related to the Devic’s Syndrome treatment market along with major factors affecting or assisting market such as opportunities, drivers, & restraints. A descriptive data covering market drivers, challenges & opportunities provided specifically for country-level and regional segmentation. This report covered detailed info related to the global Devic’s syndrome treatment market segmented based on drug type, and geography. The report also include pipeline analysis of upcoming drugs, competitive analysis of the major companies present in Devic’s Syndrome treatment market including detailed data related to the competitive landscape of the market and the recent market strategies & products pipeline.
| ATTRIBUTE |
DETAILS |
| Research Period |
2017-2027 |
| Base Year |
2018 |
| Forecast Period |
2019-2027 |
| Historical Year |
2017 |
| Unit |
USD Million |
| Segmentation |
Type of Drugs Segment (2017–2027; US$ Mn)
• Eculizumab
• Methylprednisolone
• Azathioprine
• Mycophenolate Mofetil
• Rituximab
|
|
Pipeline Analysis (2017–2027; US$ Mn)
• Satralizumab – Phase III (Hoffmann-La Roche/ Chugai Pharmaceutical)
• MEDI-551 – Phase II/III (MedImmune LLC)
• RC18 – Phase III (RemeGen, Ltd.)
|
|
Geography Segment (2017–2027; US$ Mn)
• North America (U.S., Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (Japan, China, Rest of APAC)
• Latin America (Brazil, Mexico, Rest of LATAM)
• Middle East and Africa (GCC, Rest of MEA)
|
The major companies involved in the Devic’s Syndrome treatment industry studied based on financial data, product portfolio, current press releases, and key market strategies. This report also covers attractive investment proposition analyzed based on exclusive geographical PESTEL analysis. Major companies included in the report are Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Mylan Pharmaceuticals, Inc., Chugai Pharmaceutical, MedImmune LLC, and RemeGen, Ltd. among others.
Key questions answered in this report
- Which is the most desired drug used to manage & treat Devic’s syndrome & Why?
- What are the recent market strategies followed by the key companies & competitive landscape of the Devic’s syndrome treatment market?
- Which are the current and future key geographical markets (regions and countries) in Devic’s syndrome treatment?
- Which is the fastest and largest growing Devic’s syndrome treatment segment globally?
- What are the drivers, restraints, & opportunities in the Devic’s syndrome treatment market?
